Toronto children’s hospital names first chair of AI, biomedical informatics

The Hospital for Sick Children in Toronto has named Anna Goldenberg, PhD, as its first chair of biomedical informatics and artificial intelligence, the University of Toronto recently announced.

“I feel like right now as a computer scientist, as a researcher in machine learning and AI, I can actually make a big difference in healthcare,” Goldenberg said in a report by The Globe and Mail. “It will take time, but I think we are getting closer and closer to seeing it happen.”

Goldenberg currently serves as an associate professor of computer science at the University of Toronto and a senior scientist at the hospital. Her research at both facilities focuses on using machine learning to map human disease heterogeneity and using patient data and AI to predict cardiac arrest before the heart stops beating. The new role allows Goldenberg and colleagues to expand their AI research.

Her new position with the children’s hospital will be funded in part by a $1.75 million donation from Toronto engineer and entrepreneur Amar Varma, according to the report. The hospital’s fundraising foundation will also match Varma’s, brining the total funding to $3.5 million.

See the full story below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.